Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease

NCT: NCT05536310 · TERMINATED

NCT IDNCT05536310
StatusTERMINATED
Start Date2023-08-01
Completion2024-07-09
SponsorJenaValve Technology, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

To collect information about the management of symptomatic severe Aortic Stenosis (AS) and Aortic Regurgitation (AR) using transcatheter aortic valve replacement (TAVI).

Frequently Asked Questions

What is TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease?

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease is a clinical trial registered under NCT05536310. Current status: TERMINATED.

What is the status of NCT05536310?

The current status of NCT05536310 (TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease) is: TERMINATED.

When did TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease start?

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease started on 2023-08-01.

Related Devices

PMA P250024Aortic valve, prosthesis, percutaneously deliveredJenaValve Technology, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑